Barclays PLC Buys 32,784 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Barclays PLC raised its stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 323.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,935 shares of the company’s stock after purchasing an additional 32,784 shares during the quarter. Barclays PLC owned approximately 0.14% of Actinium Pharmaceuticals worth $81,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. The Manufacturers Life Insurance Company acquired a new position in shares of Actinium Pharmaceuticals during the 2nd quarter worth about $92,000. Renaissance Technologies LLC acquired a new position in Actinium Pharmaceuticals during the second quarter worth approximately $142,000. Interchange Capital Partners LLC bought a new stake in Actinium Pharmaceuticals in the third quarter valued at approximately $37,000. Rhumbline Advisers lifted its position in shares of Actinium Pharmaceuticals by 23.4% in the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after buying an additional 7,525 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Actinium Pharmaceuticals during the 2nd quarter worth approximately $356,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Price Performance

Shares of NYSE ATNM opened at $1.31 on Friday. The firm has a market cap of $40.87 million, a PE ratio of -0.94 and a beta of 0.12. Actinium Pharmaceuticals, Inc. has a fifty-two week low of $1.10 and a fifty-two week high of $10.24. The firm has a fifty day moving average of $1.43.

Analyst Ratings Changes

Several equities analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a report on Friday, November 15th. Stephens reissued an “overweight” rating and issued a $5.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. Finally, StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

Actinium Pharmaceuticals Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).